Liposomal amphotericin B in the treatment of visceral leishmaniasis.
نویسندگان
چکیده
A case of visceral leishmaniasis unresponsive to several course of treatment with standard drugs, was successfully cured by a 21 day course (50 mg/day) of liposomal amphotericin B (AmBisome, Vestar Inc.). The efficacy of the AmBisome formulation is supported by experimental studies on Leishmania donovani infected BALB/c mice where ED50 values of AmBisome and conventional amphotericin B were 0.15-0.25 and 0.95-4.9 mg/kg, respectively. A lack of toxicity of the AmBisome formulation was noted in both studies.
منابع مشابه
Recurrent visceral leishmaniasis in an immunocompetent patient: a case report
INTRODUCTION Current treatment options for visceral leishmaniasis (pentavalent antimony, amphotericin B, liposomal amphotericin B and mitelfosine) achieve long-term clinical cure in the majority of immunocompetent patients. Disease relapse is usually provoked by T-cell number or function impairment (corticosteroid or cytotoxic therapy, transplant recipients, advanced human immunodeficiency viru...
متن کاملFirst case of pulmonary tuberculosis and visceral leishmaniasis coinfection successfully treated with antituberculosis drug and liposomal amphotericin B
KEY CLINICAL MESSAGE Successful management of cases with visceral leishmaniasis (VL) and tuberculosis is a challenge for clinicians, because a guideline for that is currently unavailable. We report the first case in Bangladesh who developed VL during her treatment for pulmonary tuberculosis and was treated successfully with multidose liposomal amhptericin B for VL.
متن کاملAntimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
We report on 4 patients (1 immunocompetent, 3 immunosuppressed) in whom visceral leishmaniasis had become unresponsive to (or had relapsed after) treatment with appropriate doses of liposomal amphotericin B. Under close follow-up, full courses of pentavalent antimony were administered without life-threatening adverse events and resulted in rapid and sustained clinical and parasitological cure.
متن کاملMultiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Visceral Leishmaniasis (VL) is an opportunistic infection amongst HIV-infected people in several endemic countries, and the clinical management of this co-infection poses several challenges. Here we describe a co-infected patient in India who failed to respond to miltefosine monotherapy and subsequently relapsed following two further (different) regimens of liposomal amphotericin B. He was then...
متن کاملPlant-derived compounds in treatment of leishmaniasis
Leishmaniasis is a neglected public health problem caused by the protozoan species belonging to the genus Leishmania affecting mostly the poor populations of developing countries. The causative organism is transmitted by female sandflies. Cutaneous, mucocutaneous, and visceral clinical manifestations are the most frequent forms of leishmaniasis. Chemotherapy still relies on the use of pentavale...
متن کاملFoamy histiocytes in a patient with visceral leishmaniasis after treatment with liposomal amphotericin B.
A seven-year-old patient was admitted to our hospital with the complaints of fever, malaise, and abdominal distention. In the bone marrow aspiration smears, leishmania amastigotes were observed. The patient was diagnosed as having visceral leishmaniasis (VL) and treated with liposomal amphotericin B (L-AMB). The authors report their observation of foamy histiocytes seen in the bone marrow aspir...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
دوره 43 7 شماره
صفحات -
تاریخ انتشار 1991